Hyper-activated platelet lysates prevent glucocorticoid-associated femoral head necrosis by regulating autophagy

Biomed Pharmacother. 2021 Jul:139:111711. doi: 10.1016/j.biopha.2021.111711. Epub 2021 May 15.

Abstract

Platelet Rich Plasma (PRP) can activate angiogenic and osteogenic pathways, making it a highly promising therapeutic agent for bone growth. Super active platelet lysate (sPL) is derived from platelet-rich plasma (PRP) through ultra-low temperature freeze-thawing. The aim of this study was to evaluate the potential therapeutic effect of sPL on glucocorticoid (GC)-induced osteonecrosis of the femoral head (ONFH). sPL increased the proliferation of GC-treated osteoblasts and endothelial cells, and inhibited apoptosis in vitro. Furthermore, sPL promoted healing of necrotic bone tissues in a rat ONFH model by restraining GC-induced apoptosis and increase autophagy of the osteoblasts. Overall, the results of this study provide a theoretical basis for the clinical application of sPL in ONFH.

Keywords: Autophagy; LC3; MTOR; Osteonecrosis of the femoral head; Platelet-rich lysate.

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Autophagy / drug effects*
  • Blood Platelets / metabolism*
  • Bone and Bones / drug effects
  • Cell Line
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Endothelial Cells / drug effects
  • Femur Head / drug effects*
  • Femur Head Necrosis / chemically induced*
  • Femur Head Necrosis / prevention & control*
  • Glucocorticoids / adverse effects*
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Male
  • Osteoblasts / drug effects
  • Osteogenesis / drug effects
  • Platelet-Rich Plasma / metabolism*
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Glucocorticoids